Hemay-020

N/A

Report date: 2026/05/08 20:02:52
NME

Base Information

Drug NameHemay-020
Drug Alias NameHemay-020
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitors
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTianjin Hemay Pharmaceutical Co LtdHainan General Sanyang Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesTianjin Hemay Bio-Tech Co LtdHainan General Sanyang Pharmaceutical Co Ltd
Inactive CompaniesTianjin Hemay Pharmaceutical Co Ltd
Active IndicationsSolid tumours
Inactive IndicationsCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksN/A